Parvovirus 4 in Individuals with Severe Hemophilia A and Matched Control Group
Background: Hemophilia is a well-known bleeding disorder with worldwide distribution. Replacement therapy, using plasma-derived or recombinant coagulation factors, comprises a gold standard regimen for the treatment. Regardless of the advancements made in viral inactivation methods in the production of plasma-derived coagulation factors, the possibility of transmission of new viral infections remained as a noticeable concern yet. The aim of the current study was to investigate the status of parvovirus 4 (PARV4) in severe hemophilia A, von Willebrand disease (vWD), and healthy control.
Materials and Methods: In the current case-control study, 76 patients with hemophilia and vWD and 60 individuals from their family members entered the study. Nested PCR used to determine the presence of PARV4 in study subjects (76 cases). To characterize the PARV4 genotype, positive samples subjected to sequencing and phylogenetic analysis.
Results: PARV4 genome detected in 11 (14.47%) patients with bleeding disorders. Among whom, nine patients (14.75%) were with severe hemophilia A and two (13.33%) patients with vWD. Only five healthy controls (8.33%) were positive for PARV4. All PARV4 sequences were found to be genotype 1.
Conclusion: PARV4 infection in patients with hemophilia and vWD was higher than the control group. While detection of PARV4 DNA in patients with bleeding disorders may not necessarily reflect a clinical urgency, future investigations are needed to define the clinical significance of PARV4. It seems the detection of the virus immune signature of PARV4 infection, particularly in the context of acute and persistent infections, needs to focus on cellular and tissue targets.
2. Mansouritorghabeh H, Rezaieyazdi Z, Bagheri M. Successful use of factor VIII concentrate and fresh frozen plasma for four dental extractions in an individual with combined factor V and VIII deficiency. Transfus Med Hemo 2009;36(2):138-9.
3. Fryer J, Hubbard A, Baylis S. Human parvovirus PARV4 in clotting factor VIII concentrates. Vox Sang 2007;93(4):341-7.
4. Jones MS, Kapoor A, Lukashov VV, et al. New DNA viruses identified in patients with acute viral infection syndrome. J Virol. 2005;79(13):8230-6.
5. Touinssi M, Reynaud‐Gaubert M, Gomez C, et al. Parvovirus 4 in French in‐patients: A study of hemodialysis and lung transplant cohorts. J Med Virol. 2011;83(4):717-20.
6. Simmonds P, Manning A, Kenneil R, et al. Parenteral transmission of the novel human parvovirus PARV4. Emerg Infect Dis. 2007; 13(9):1386-8.
7. Simmons R, Sharp C, McClure CP, et al. Parvovirus 4 infection and clinical outcome in high-risk populations. J Infect Dis. 2012:205(12): 1816-1820.
8. Yu X, Zhang J, Hong L, et al. High prevalence of human parvovirus 4 infection in HBV and HCV infected individuals in shanghai. PloS One. 2012;7(11):e29474.
9. Asiyabi S, Nejati A, Shoja Z, et al. First report of human parvovirus 4 detection in Iran. J Med Virol. 2016;88(8):1314-8.
10. Maple PA, Beard S, Parry RP, et al. Testing UK blood donors for exposure to human parvovirus 4 using a time‐resolved fluorescence immunoassay to screen sera and Western blot to confirm reactive samples. Transfusion. 2013;53 (10 Pt 2):2575-84.
11. Eis‐Hübinger AM, Drexler JF, Reber U, et al. Absence of detection of novel human parvoviruses in German plasma donations. Transfusion. 2010;50(1):266-7.
12. Touinssi M, Brisbarre N, Picard C, et al. Parvovirus 4 in blood donors, France. Emerg Infect Dis. 2010;16(1):165-6.
13. Fryer JF, Delwart E, Hecht FM, et al. Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion. 2007;47(6):1054-61.
14. Sharp CP, Vermeulen M, Nébié Y, et al. Epidemiology of human parvovirus 4 infection in sub-Saharan Africa. Emerg Infect Dis. 2010;16(10):1605-1607.
15. Simmons R, Sharp C, Levine J, et al. Evolution of CD8+ T cell responses after acute PARV4 infection. J Virol. 2013;87(6):3087-96.
16. Sharp CP, Lail A, Donfield S, et al. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion. 2012;52(7):1482-9.
17. Schneider B, Fryer J, Oldenburg J, et al. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4. Haemophilia. 2008;14(5):978-86.
18. Javanmard D, Ziaee M, Ghaffari H, et al. Human parvovirus B19 and parvovirus 4 among Iranian patients with hemophilia. Blood Res. 2017;52(4):311-5.
19. Norja P, Lassila R, Makris M. Parvovirus transmission by blood products–a cause for concern? Br J Haematol. 2012;159(4):385-93.
20. Panning M, Kobbe R, Vollbach S, et al. Novel human parvovirus 4 genotype 3 in infants, Ghana. Emerg Infect Dis. 2010; 16(7): 1143-6.
21. Chaves A, Ibarra‐Cerdeña CN, López‐Pérez AM, et al. Bocaparvovirus, Erythroparvovirus and Tetraparvovirus in New World Primates from Central America. Transbound Emerg Dis. 2020; 67(1): 377-87.
22. Mansouritorghabeh H, Manavifar L, Banihashem A, et al. An investigation of the spectrum of common and rare inherited coagulation disorders in north-eastern Iran. Blood Transfus. 2013;11(2):233-40.
23. Lurcharchaiwong W, Chieochansin T, Payungporn S, et al. Parvovirus 4 (PARV4) in serum of intravenous drug users and blood donors. Infection. 2008;36(5):488-91.
24. Fryer JF, Kapoor A, Minor PD, et al. Novel parvovirus and related variant in human plasma. Emerg Infect Dis. 2006;12(1):151-4.
25. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W. Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22(22):4673-80.
26. Tamura K, Peterson D, Peterson N, et al. Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28(10):2731-9.
27. Sharp CP, Lail A, Donfield S, et al. High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis. 2009;200(7):1119-25.
28. Slavov SN, Kashima S, Rocha‐Junior MC, et al. Human parvovirus 4 in Brazilian patients with haemophilia, beta‐thalassaemia major and volunteer blood donors. Haemophilia. 2015;21(1):e86-8.
29. Benjamin LA, Lewthwaite P, Vasanthapuram R, et al. Human Parvovirus 4 as Potential Cause of Encephalitis in Children, India. Emerg Infect Dis. 2011;17(8):1484-7.
30. Lavoie M, Sharp CP, Pépin J, et al. Human parvovirus 4 infection, Cameroon. Emerg Infect Dis. 2012;18(4):680-3.
31. Sancho-Shimizu V, de Diego RP, Jouanguy E, et al. Inborn errors of anti-viral interferon immunity in humans. Curr Opin Virol. 2011;1(6):487-96.
32. Delwart E. Human parvovirus 4 in the blood supply and transmission by pooled plasma‐derived clotting factors: does it matter? Transfusion. 2012;52(7):1398-403.
33. Bernardin F, Operskalski E, Busch M, et al. Transfusion transmission of highly prevalent commensal human viruses. Transfusion. 2010;50(11):2474-83.
34. Yu X, Zhang J, Hong L, et al. High prevalence of human parvovirus 4 infection in HBV and HCV infected individuals in shanghai. PLoS One. 2012;7(1):e29474.
35. Touinssi M, Reynaud‐Gaubert M, Gomez C, et al. Parvovirus 4 in French in‐patients: A study of hemodialysis and lung transplant cohorts. J Med Virol. 2011;83(4):717-20.
36. Ma YY, Guo Y, Zhao X, et al. Human parvovirus PARV4 in plasma pools of Chinese origin. Vox Sang. 2012;103(3):183-5.
37. Lahtinen A, Kivela P, Hedman L, et al. Serodiagnosis of primary infections with human parvovirus 4, Finland. Emerg Infect Dis. 2011;17(1):79-82.
38. Schneider B, Fryer JF, Reber U, et al. Persistence of novel human parvovirus PARV4 in liver tissue of adults. J Med Virol. 2008;80(2):345-51.
39. Simmonds P, Manning A, Kenneil R, et al. Parenteral transmission of the novel human parvovirus PARV4. Emerg Infect Dis. 2007;13(9):1386-8.
|Issue||Vol 15 No 3 (2021)|
|Hemophilia; Parvovirus 4; von Willebrand disease; Viral infection|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|